This company has gained almost 10,000 percent on the stock exchange since January. Incredible result
Regencell Bioscience products are not revenue yet, and the full registration path is just formed. However, the concept of combining phytotherapy with clinical trial methodology attracts the attention of investors, Especially those looking for early, unconventional projects.
RGC shares increased in just four months from around $ 5. To the historic maximum $ 534 Currently, they are near $ 465.
In March, two events initiated explosive dynamics: firstly, the president and founder of YAT-GAI AU financed the redemption of 652,982 shares from an institutional investor $ 9.50 from his own resources. per item, increasing its shares to 86 percent. capital.
Secondly, the company pre -announced the positive results of the second attempt to effectiveness, in which standardized TCM formulas They showed a statistically significant improvement in the basic symptoms of ADHD and ASD with a favorable safety profile.
Special offer
It doesn't happen too often
An extremely rare market system has been applied. Due to the extremely low free float (just over 800,000 shares) and the dominant shares of Insider (approx. 94 percent) A small wave of demand was enough to conquer the course violently. Shortly after the clinical communication, the indicator of the use of the loan pool reached 86 percent, and the fee for short sales exceeded 600 percent. annually, practically blocking the possibility of opening new items. Later, forced backups of short items became fuel for a series of daily increases exceeding 40 percent.
In the first week of May, the effect took on a parabolic shape: On May 6, the shares increased by 42 percent, the next day by another 29 %, and on May 9 closed to $ 366.01.which has already been commented on by the media dealing with catching the momentum on “small biotechnology”.
Regencell Bioscience (symbol: RGC) has developed over 9,200 percent profit on the stock exchange from January this year.
|
Yahoo finance
Speculative capital has also arrived from social media and day-trader forums-many investors pointed out that with nominal capitalization below $ 5 billion. Any additional good clinical message can easily add several hundred million to the valuation.
At the current stage, however, Regekell offers more questions than answers. The reported research was not randomized, which raises the legitimate caution of the regulators. The company plans the central production of GMP in Hong Kong and subsequent, more stringent research, but without the schedule of entry to the phase III or the clear registration path in the USA or the EU, the technological risk remains high.
Added to this is the unprecedented variability of the course: fluctuations of 30-50 percent During one session they became the norm, and liquidity in many days is limited to tens of thousands of actions, which makes it Stop-Loss orders may not be completed at the assumed price.
Note: The valuations included in the text are only informative and do not constitute a recommendation for the purchase or sale of financial products.
